Lantern Pharma Inc (LTRN)

$6.27

+0.04

(+0.64%)

Market is closed - opens 7 PM, 28 May 2024

Insights on Lantern Pharma Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 67.5% return, outperforming this stock by 35.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 238.5% return, outperforming this stock by 294.6%

Performance

  • $6.15
    $6.80
    $6.27
    downward going graph

    1.91%

    Downside

    Day's Volatility :9.5%

    Upside

    7.74%

    downward going graph
  • $2.38
    $10.77
    $6.27
    downward going graph

    62.04%

    Downside

    52 Weeks Volatility :77.9%

    Upside

    41.78%

    downward going graph

Returns

PeriodLantern Pharma IncSector (Health Care)Index (Russel 2000)
3 Months
45.81%
-2.3%
0.0%
6 Months
52.55%
10.1%
0.0%
1 Year
32.28%
13.0%
0.0%
3 Years
-56.09%
16.4%
-19.8%

Highlights

Market Capitalization
67.0M
Book Value
$3.82
Earnings Per Share (EPS)
-1.47
Wall Street Target Price
18.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-21.81%
Return On Equity TTM
-32.93%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-17.9M
Diluted Eps TTM
-1.47
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.23
EPS Estimate Next Year
-2.02
EPS Estimate Current Quarter
-0.43
EPS Estimate Next Quarter
-0.56

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Lantern Pharma Inc(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
7
Hold
3
3
2
Sell
3
3
00

Analyst Forecast

What analysts predicted

Upside of 187.08%

Current $6.27
Target $18.00

Technicals Summary

Sell

Neutral

Buy

Lantern Pharma Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Lantern Pharma Inc
Lantern Pharma Inc
14.84%
52.55%
32.28%
-56.09%
-58.06%
Moderna, Inc.
Moderna, Inc.
56.91%
114.37%
31.74%
-1.57%
673.49%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
10.59%
23.42%
35.86%
97.78%
219.88%
Novo Nordisk A/s
Novo Nordisk A/s
8.15%
30.97%
67.5%
238.49%
467.54%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
14.9%
30.49%
37.37%
118.89%
164.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Lantern Pharma Inc
Lantern Pharma Inc
NA
NA
NA
-2.23
-0.33
-0.22
NA
3.82
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.6
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.99
28.99
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.75
46.75
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.23
29.23
0.53
17.14
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Lantern Pharma Inc
Lantern Pharma Inc
Sell
$67.0M
-58.06%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$63.9B
673.49%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
219.88%
28.99
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$605.7B
467.54%
46.75
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$116.3B
164.5%
29.23
39.46%

Institutional Holdings

  • Vanguard Group Inc

    3.40%
  • Goss Wealth Management LLC

    1.54%
  • Geode Capital Management, LLC

    0.88%
  • CM Management, LLC

    0.74%
  • Carlson Capital LP

    0.56%
  • Commonwealth Equity Services Inc

    0.55%

Company Information

lantern pharma is leading a wave of innovation in cancer treatment that we believe will bring the best therapies to patients who are most likely to respond. we are pioneering precision medicine approach to cancer by tailoring promising drug programs to the right patients. our approach is to use biomarker based genetic screening to identify and treat patients that would benefit most from our drugs. we believe this approach will reduce the cost of development and increase the speed to market. our strategy is to acquire or partner with promising drug and diagnostic companies to move forward promising personalized medicine programs for cancer patients.

Organization
Lantern Pharma Inc
Employees
21
CEO
Mr. Panna Sharma PH.D.
Industry
Commercial Services

FAQs